The US FDA took the unusual step of publicly rebutting a series of media reports raising questions about its oversight of generic drug manufacturers, hoping to restore any wavering confidence in its facility inspection and pharmacovigilance work.
Commissioner Scott Gottlieb and Center for Drug Evaluation and Research Director Janet Woodcock issued a 2,685-word statement Feb. 22...




